Andrew W. Williams

Andrew W. Williams, PhD

Counsel | Biotechnology
617.646.8194 LinkedIn Profile


  • BS, Biochemistry, University of Iowa, with honors
  • PhD, Molecular Biophysics and Biochemistry, Yale University
  • MPhil, Molecular Biophysics and Biochemistry, Yale University
  • JD, The George Washington University Law School, highest honors

Key Technologies

  • Biological Therapeutics
  • Antibodies & Immunotherapies 
  • Cancer Therapies
  • Gene Therapies
  • Nucleic-Acid-Based Therapies
  • Cell Therapies
  • Chimeric Antigen Receptors
  • Gene Editing
  • Extracellular Vesicles
  • Vaccines
  • Molecular Diagnostics
  • Next-Generation Sequencing (NGS)

Practice Groups

Admitted to Practice

  • Illinois
  • Massachusetts
  • US Patent and Trademark Office
  • US Supreme Court 
  • US Court of Appeals for the Federal Circuit
  • US District Court for the Northern District of Illinois
  •  US District Court for the Western District of Wisconsin


  • Boston


Andrew Williams has more than 20 years of experience advising clients in the life science industry in all areas of intellectual property matters, including patent procurement, patent enforcement, and strategic counseling. He believes that he can best meet the needs of his clients because of his wide-ranging experience. For example, Andrew’s experience asserting and defending patents in federal court and the Patent Office has been invaluable in helping him obtain commercially valuable patent protection for his clients. 

Andrew has extensive experience representing both large and small companies, as well as start-ups, universities, and research institutions. He has experience both litigating and counseling generic drug patent disputes arising under the Hatch-Waxman Act and has counseled on biosimilars and the Biologics Price Competition and Innovation Act (BPCIA).     

Andrew is an active member of the IP community and has authored articles for various legal publications including Law360, Intellectual Property Magazine, Intellectual Property Today, and Expert Opinion on Therapeutic Patents and Biosimilar Developments. In particular, Andrew has written extensively on issues specific to AIA-related PTAB trials, with a particular focus on life science-related IPRs and PGRs; the emergence of BPCIA-related biosimilars and corresponding patent resolution strategies; efforts to draft legislation to curb abusive patent litigation; and ethical issues related to patent practice.

Prior to joining Wolf Greenfield, Andrew was a partner at an intellectual property law firm. He was also a founding member and Chair of the firm’s PTAB Trials Practice.


  • Boston Intellectual Property Law Association
  • Federal Circuit Bar Association 
  • American Bar Association 
  • American Association for the Advancement of Science


  • Top Author in JD Supra Readers’ Choice 2017 (“Pharmaceutical Industry”) and 2016 (“Patents”)
  • Extern, Hon. Richard Linn, US Court of Appeals for the Federal Circuit


See All Publications

Other Publications

  • “The State Of Pharma Litigation After The Supreme Court's TC Heartland Case,” Life Science Leader (June 2018)
  • “Supreme Court Holds that IPR Proceedings do not Violate Article III or the Seventh Amendment in Oil States v. Greene’s Energy,” MBHB Snippets Alert (April 2018)
  • “Motions to Amend at the PTAB after Aqua Products, Inc. v. Matal – What’s a Patent Owner to Do?,” MBHB Snippets Newsletter (Winter 2018)
  • “CAFC Shifts the Burden for IPR Claim Amendments from the Patent Owner to the Petitioner,” MBHB Snippets Alert (October 2017)
  • “Reports of the Death of the Patent Dance Have Been Slightly Exaggerated,” The Pharma Letter (July 2017)
  • “SCOTUS: Supreme Court Lifts Biosimilars by Allowing Early Commercial Marketing Notice,” MBHB Snippets Alert (June 2017)
  • “Can SCOTUS solve the biosimilar ‘enigma’?,” Intellectual Property Magazine (March 2017)
  • “10 Years Of MedImmune: How Patent Owners Fared,” (February 2017)
  • “Post-Grant Review Estoppel – Looking Forward by Looking Back at Estoppel in Inter-Partes and Covered-Business-Method Review,” MBHB Snippets Newsletter (Winter 2017)
  • “Some Clarity for Biosimilar Applicants,” Intellectual Property Magazine (September 2016)
  • Cuozzo Speed Technologies, LLC v. Lee – Supreme Court Holds Status Quo,” MBHB Snippets Alert (June 2016)
  • “Supreme Court Rules District Courts to Have More Discretion in Finding Willful Patent Infringement by Malicious Pirates,” MBHB Snippets Alert (June 2016)
  • “The PTAB at the Supreme Court – and the Federal Circuit’s Response,” IP Watchdog (April 2016)
  • “Standing Alone – The Current Status of the BPCIA’s Notice of Commercial Marketing,” MBHB Snippets Newsletter (Spring 2016)
  • “One Year After In re Cuozzo,” Intellectual Property Magazine Online (March 2016)
  • “The PTAB and the Federal Circuit – One Year Later,” MBHB Snippets Newsletter (Winter 2016)
  • “5 Questions To Ask About Biosimilars In 2016” Biosimilar Development Online (January 2016)
  • “The BIO International Convention in Philadelphia,” Intellectual Property Magazine (September 2015)
  • "Amgen v. Sandoz - Did Fed. Circ. Doom The New Biosimilar Approval Pathway?," MBHB Snippets Newsletter (Summer 2015)
  • “Biosimilars at the Federal Circuit – Will this be the Last Dance?,” IP Watchdog (June 2015)
  • “Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?,” BIOTechNOW (June 2015)
  • "First U.S. Biosimilar Application Approved — But What About the Patent Issues?,” iBIO's Biological Quarterly (March 2015)
  • “Federal Circuit Sides with Patent Office in First IPR Final Written Decision Review,” MBHB Snippets Alert (February 2015)
  • "Just What Does It Take to Amend Claims Before the PTAB?: Lessons Learned From the Board," MBHB Snippets Newsletter (Winter 2015)
  • Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. – U.S. Supreme Court Requires Trial Court’s Findings of Fact in Claim Construction Be Given Deference,” MBHB Snippets Alert (January 2015)
  • "How would patent reform legislation in the United States impact the pharmaceutical industry?," Expert Opinion on Therapeutic Patents (November 2014)
  • "Patent Reform Legislation Off The Table For Now," BIOTechNOW (June 2014)
  • "Senate Judiciary Committee Takes Up, Then Tables, Patent Reform," Today's General Counsel (April 2014)
  • " A Rebuttal to The Economist's 'Stalking Trolls'," (March 2014)

Recent News